AEON Biopharma shares surge 13.33% intraday after FDA Type 2a meeting and shareholder-approved debt restructuring.

AEON Biopharma surged 13.33% intraday following two key developments: the completion of its FDA BPD Type 2a meeting for ABP-450, a biosimilar to BOTOX, and shareholder approval of debt-restructuring transactions. The FDA meeting, a procedural milestone in regulatory clearance, signals progress toward potential market entry, while the Daewoong note exchange reduced outstanding debt and simplified the capital structure, strengthening the balance sheet. These events, announced on January 21, 2026, directly aligned with the intraday rally, reflecting investor optimism about regulatory advancements and financial stability.